Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004

Abstract

We conducted a cytogenetic analysis of 642 children with de novo acute myeloid leukemia (AML) treated on the AML-Berlin-Frankfurt-Münster (BFM) 04 protocol to determine the prognostic value of specific chromosomal aberrations including monosomal (MK⁺), complex (CK⁺) and hypodiploid (HK⁺) karyotypes, individually and in combination. Multivariate regression analysis identified in particular MK⁺ (n=22) as a new independent risk factor for poor event-free survival (EFS 23±9% vs 53±2% for all other patients, P=0.0003), even after exclusion of four patients with monosomy 7 (EFS 28±11%, P=0.0081). CK⁺ patients without MK had a better prognosis (n=47, EFS 47±8%, P=0.46) than those with MK⁺ (n=12, EFS 25±13%, P=0.024). HK⁺ (n=37, EFS 44±8% for total cohort, P=0.3) influenced outcome only when t(8;21) patients were excluded (remaining n=16, EFS 9±8%, P<0.0001). An extremely poor outcome was observed for MK⁺/HK⁺ patients (n=10, EFS 10±10%, P<0.0001). Finally, isolated trisomy 8 was also associated with low EFS (n=16, EFS 25±11%, P=0.0091). In conclusion, monosomal karyotype is a strong and independent predictor for high-risk pediatric AML. In addition, isolated trisomy 8 and hypodiploidy without t(8;21) coincide with dismal outcome. These results have important implications for risk stratification and should be further validated in independent pediatric cohorts.

Figure 1

(a) Schematic presentation of overlapping groups of patients with AML according to their cytogenetically defined karyotype. (b) Event-free survival of patients with complex (CK) and monosomal karyotype (MK). (c) EFS for patients with MK and hypodiploid karyotype (HK).

Figure 2

(a) Distribution of monosomies in patients with monosomal karyotype. n=number of monosomies; MK, monosomal karyotype. (b) EFS for patients with MK compared to patients with standard risk (SR), intermediate (MR) and other high-risk factors. (c) OS for patients with MK compared to patients with SR, intermediate risk and other high-risk factors. Definition of intermediate risk according to the AML-BFM 2012 protocol, defined as no favorable or high-risk criteria.